The FreeStyle Libre by Abbott can provide prick-free on-demand sugar readings that offer detailed insights with just a scan ...

Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have ...

Worldwide Medical Devices sales increased 11.7% on a reported basis and 13.3% on an organic basis in the third quarter, ...

With an in-line performance expected in Q3, ABT stock may trade sideways next week. However, we would watch out for its ...

Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...

The planned launch of Omnipod 5 with Abbott's Freestyle Libre 2 Plus sensor is likely to drive further growth in the U.S. markets.

Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are ...

Q3 2024 Earnings Call Transcript October 16, 2024 Abbott Laboratories beats earnings expectations. Reported EPS is $1.21, ...

Meanwhile, Abbott's FreeStyle Libre and FreeStyle Libre 2 flash CGM systems remain available to patients and listed on the NHS Drug Tariff. The FreeStyle Libre 3 system consists of the sensor ...

ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna ...

Abbott Laboratories ABT reported third-quarter 2024 adjusted earnings per share (EPS) of $1.21, which beat the Zacks ...

Freestyle Libre CGM device is also on a great trajectory ... The company repurchased shares worth $0.2 million in the latest ...